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Analysis of Signal Transduction Pathways Regulating
Cytokine-Mediated Fc Receptor Activation on Human
Eosinophils1
Madelon Bracke, Paul J. Coffer, Jan-Willem J. Lammers, and Leo Koenderman2
Igs can be potent stimulants of eosinophil activation since interaction with IgA or IgG-coated particles can lead to eosinophil
degranulation. We have investigated the comparative roles of mitogen-activated protein (MAP) kinases (MAPKs; ERK1/2 and
p38) and phosphatidylinositol-3 kinase (PI3K) in the priming and regulation of Fc receptor functioning on human eosinophils
utilizing a MAPK kinase (MEK) inhibitor (PD98059), a p38 inhibitor SB203580, and the widely used PI3K inhibitors wortmannin
and LY294002. We demonstrate that priming of human eosinophils with Th2-derived cytokines, IL-4 and IL-5, differentially
activate phosphotyrosine-associated PI3K and ERK and p38 MAP kinases. This activation can be inhibited by pre-incubation with
wortmannin or LY294002, PD98059, and SB203580, respectively. Analysis of the effects of the inhibitors on rosette formation
between human eosinophils and IgA- or IgG-coated beads revealed that activation of MEK was not required for IgA binding after
priming with IL-4 or IL-5. However, inhibition of MEK did inhibit IL-5-primed binding of IgG-beads. The rosette formation of
primed eosinophils with IgA-beads could be completely inhibited by wortmannin and LY294002 treatment, demonstrating a
critical role for PI3K. Interestingly, inhibition of the p38 pathway also resulted in a complete blockade of IgA rosette formation.
This work demonstrates regulatory control by inside-out signaling of Fc receptors by various cytokines on human eosinophils.
Thus in vivo the local production of Th2-derived cytokines will regulate the effector functions of Fc receptors. The Journal of
Immunology, 1998, 161: 6768–6774.
E osinophilic granulocytes play an important role in hostdefense against parasites, and the regulation of their ac-tivation through the interaction with cytokines and che-
moattractants is critical in regulating their functioning. Eosinophils
are also implicated in the pathogenesis of a variety of inflamma-
tory diseases which are associated with tissue damage, for example
allergic asthma (1, 2). Although the exact role of eosinophils in
allergic inflammation remains to be elucidated, increased numbers
are regularly observed in peripheral blood of patients with allergic
asthma. Furthermore, in these individuals, eosinophils exhibit a
preactivated or “primed” state, indicated by an increased respon-
siveness toward distinct stimuli (3, 4). In addition, eosinophil-de-
rived products are found in lung tissue, such as active eosinophil
cationic protein and major basic protein. The release of such toxic
mediators results in destruction and damage of the respiratory ep-
ithelial tissue and can lead to airway hyperresponsiveness (5, 6).
Also, production of toxic oxygen metabolites during the so-called
respiratory burst and synthesis and secretion of bioactive lipid me-
diators contribute to airway hyperreactivity (7–9).
Despite much knowledge concerning the effector functions of
eosinophils in vivo, relatively little is known about the processes
that lead to activation of eosinophils in the bronchial compartment.
Several mechanisms are involved in these processes, including ac-
tivation via receptors for adhesion molecules, complement factors,
and Igs (10). These receptors are potent signaling molecules in
vitro, albeit optimal only after priming with cytokines or
chemotaxins (11, 12).
Binding of cytokines to specific transmembrane receptors re-
sults in intracellular increases in tyrosine phosphorylation and ac-
tivation of distinct signal transduction pathways (13). In vitro,
priming of eosinophils with IL-5 potentates effector functions such
as respiratory burst activation, migration, and platelet-activating
factor release (14–17). Although compared with IL-5 little is
known about effects of IL-4 priming on eosinophil function, it can
also serve as a priming agent for eosinophil chemotaxis (18). Fur-
thermore, functioning of IgA Ig receptors on eosinophils is
strongly modulated by both IL-5 and IL-4 (19), albeit with differ-
ent activation kinetics.
The receptor for Ig A is a possible candidate for final eosinophil
activation at allergic inflammatory sites, since IgA is abundantly
present on mucosal surfaces and IgA-coated particles potently in-
duce eosinophil degranulation (20–22). Receptors for IgA are de-
scribed on many cell types, including monocytes, neutrophils, and
eosinophils (23–25). At present not much is known about the ac-
tivation and functioning of FcaRs on eosinophils in contrast with
the better defined FcgRII (26). Binding of IgG-coated magnetic
beads or IgG-coated erythrocytes to eosinophils is sensitive for
priming by IL-5 and granulocyte-macrophage CSF, but not influ-
enced by priming with IL-4 (19, 27).
To investigate which signal transduction pathways are involved in
the regulation of Fc receptors on human eosinophils, we have studied
the activation of phosphatidylinositol 3-OH kinase (PI3K),3 and mi-
togen-activated protein kinases (MAPK); i.e., extracellular regulated
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kinase (ERK)-1, ERK2, and p38 kinase, in freshly isolated eosino-
phils from normal donors. Specific inhibitors of those kinases were
used to study the involvement of particular signaling pathways in the
activation of FcaR and FcgRII on eosinophils.
Materials and Methods
Reagents
Percoll was obtained from Pharmacia (Uppsala, Sweden). FMLP and OVA
were purchased from Sigma (St. Louis, MO). Human serum albumin
(HSA) and purified human serum IgG (without traces of other Igs) were
from the Central Laboratory of the Netherlands Red Cross Blood Trans-
fusion Service (Amsterdam, The Netherlands). Purified human serum IgA
(.20 mg/ml) was obtained from Cappel (Malvern, PA). It contained no
detectable trace of IgG, IgM, or non-Ig serum proteins. Human rIL-5 was
a gift from Dr D. Fattah (Glaxo/Wellcome, Stevenage, U.K.). IL-4 was a
gift from Dr F. Kalthoff (Sandoz Forschungsinstitut, Vienna, Austria). Rab-
bit polyclonal ERK1 (C-16), ERK2 (C-14), and p38 MAPK (C-20) antisera
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The
antiphosphotyrosine polyclonal MAPK and p38 MAPK Abs were obtained
from New England Biolabs (Berverly, MA). Pharmacological inhibitors
wortmannin, LY294002, PD98059, and SB203580 were purchased form
BioMol (Plymouth Meeting, PA).
Isolation of eosinophils
Blood was obtained from healthy volunteers from the Red Cross Blood
Bank (Utrecht, The Netherlands). Mixed granulocytes were isolated from
the buffy-coat of 500 ml blood anticoagulated with 0.4% (w/v) trisodium
citrate (pH 7.4) as previously described (28). Mononuclear cells were re-
moved by centrifugation over isotonic Percoll (1.078 g/ml). After lysis of
the erythrocytes with an ice-cold NH4Cl solution, the granulocytes were
washed and resuspended in RPMI 1640 (Life Technologies, Paisley, U.K.)
with 0.5% (w/v) HSA.
Granulocytes were incubated for 30 min at 37°C to restore the initial
density of the cells. Thereafter, the cells were washed and resuspended in
PBS supplemented with 0.5% HSA and 13 mM trisodium citrate, and in-
cubated with FMLP (10 nM) for 10 min at 37°C to decrease the specific
gravity of the neutrophils, but not that of the eosinophils. Subsequently,
eosinophils were obtained by centrifugation (20 min at 1000 3 g) over
isotonic Percoll (density 1.084 g/ml, layered on percoll with a density of
1.1 g/ml), washed, and resuspended in incubation buffer (20 mM HEPES,
132 mM NaCl, 6 mM KCl, 1 mM MgSO4, 1.2 mM KH2PO4, supplemented
with 5 mM glucose, 1.0 mM CaCl2, and 0.5% (w/v) HSA). Purity of eo-
sinophils was 97% (60.5 SEM), and recovery was usually 80–90%. This
procedure leads to the isolation of relatively unprimed eosinophils com-
pared with conventionally used isolation procedures with immunomagnetic
beads (29).
MAPK activity
Eosinophils were isolated as described above and incubated at 37°C for 30
min. After pretreatment with or without PD98059, SB203580, LY294002,
or wortmannin and stimulation with IL-4 or IL-5, cells (2 3 106 cells) were
washed twice in ice-cold PBS and lyzed in lysis buffer (50 mM Tris-HCl,
pH 7.5, 100 mM NaCl, 50 mM NaF, 5 mM EDTA, 40 mM b-glycero-
phosphate, 1% Triton X-100) supplemented with Na3VO4 (1 mM), apro-
tinin (10 mg/ml), leupeptin (10 mg/ml), and 1 mM PMSF. Lysates were
precleared for 30 min at 4°C with protein A-Sepharose beads and subse-
quently, MAPK was immunoprecipitated with 1 mg of ERK1, ERK2, or
p38 polyclonal antisera for 1 h at 4°C on a rotating wheel. Protein-A
Sepharose was then added for a further 1 h at 4°C. After washing twice
with lysis buffer with phosphatase inhibitors, samples were washed twice
with kinase buffer (30 mM Tris-HCl, pH 8.0, 20 mM MgCl2, 2 mM MnCl2,
10 mM rATP, 10 mM MBP) without ATP. Precipitates were then incubated
in 25 ml kinase buffer with 0.3 mCi [g-32P]ATP for 20 min at 30°C. Re-
action was stopped by the addition of 53 Laemmli sample buffer. Samples
were separated by electrophoresis on 15% SDS-polyacrylamide gels. MBP
phosphorylation was detected by autoradiography.
p38 MAPK phosphorylation
Eosinophils were isolated as described above and incubated at 37°C for 30
min in incubation buffer. For detection of phosphorylation of p38 MAPK,
eosinophils (0.5 3 106 per condition) were washed twice in ice-cold PBS
after stimulation and lyzed in lysis buffer (1% Triton-X100, 50 mM Tris-
Cl, pH 8.0, 100 mM NaCl) with phosphatase inhibitors and subsequently
boiled for 5 min after addition of 53 sample buffer. Total cell lysates were
analyzed on 15% SDS-polyacrylamide gels. Proteins were transferred to
Immobilon-P and incubated with blocking buffer (Tris buffered saline/
Tween 20 (TBST) supplemented with 1 mM EDTA and 0.6% BSA) with
polyclonal phospho-p38 MAPK antisera. Detection was with ECL (Am-
ersham, Rainham, U.K.). Blots were reprobed with p38 MAPK Ab.
Preparation of Ig-coated magnetic dynabeads
Serum IgG and serum IgA were coated to uncoated magnetic dynabeads
(M-450, Dynal, Norway). Beads were washed twice with PBS (pH 8.5) and
brought to a concentration of 45 mg/ml. Proteins were added at a final
concentration of 1 mg/ml to the beads and mixed overnight at 4°C. The
next day the beads were washed with borate buffer (0.5 M NaCl, 0.2 M
H3BO3, and 0.02 M NaOH, pH 8.6) and blocked with 0.1 M lysine mo-
nohydrochloride (pH 8.6) in borate buffer for 2 h at room temperature.
After two washes with 0.1 M acetate buffer (pH 4), beads were washed
once with PBS with 1% (w/v) BSA. Until use, the beads were stored at 4°C
in PBS/BSA at a concentration of 30 mg/ml (4 3 108 beads/ml). Before the
rosette assay, beads were resuspended in 20% (w/v) HSA and left for 20
min at room temperature.
Rosette assay
Purified eosinophils were washed with Ca21-free incubation buffer con-
taining 0.5 mM EGTA and brought to a concentration of 8 3 106 cells/ml.
A 50 ml cell suspension (0.4 3 106 cells) was incubated at 37°C. For
priming, IL-5 and IL-4 were added 1:10, with final concentrations of 1029
M. Cells were incubated with IL-4 for 5 min and with IL-5 for 15 min at
37°C. After priming, the beads were added in a ratio of 3.5 beads/cell. Cells
and beads were mixed briefly and pelleted for 15 s at 100 rpm. Normally,
eosinophils were incubated with beads during 30 min at 37°C. In the case
of IL-4 primed eosinophils, beads and cells were incubated together for
only 20 min. Longer incubation resulted in lower levels of binding, due to
the transient effect of IL-4 priming, as described previously (19).
After incubation cells were resuspended vigorously and rosettes were
evaluated under a microscope. All cells that had bound two beads or more
were defined as rosettes. One hundred cells were scored, and the number of
beads that were bound to the cells was counted. The amount of beads
bound to a total of 100 cells (bound and unbound to beads) was designated
as the rosette index. Previously we have demonstrated that the rosetting
method with magnetic beads is very specific since 1) there is no apprecia-
ble background binding of eosinophils to control beads coated with OVA
and 2) relevant blocking mAbs against Fc receptors inhibit the
response (19).
Inhibition of rosette assays with specific PI3K, MAPK kinase
(MEK), and p38 inhibitors
For priming-inhibition studies, cells were pre-incubated with specific in-
hibitors before priming with cytokines. Cells were incubated with PI3K
inhibitors wortmannin and LY294002 for 15 min at final concentrations of
20 nM and 1 mM, respectively. The p38 inhibitor SB203580 was incubated
for 15 min at a concentration of 1 mM, while incubation with the MEK
inhibitor PD98059 was for 30 min at a concentration of 10 or 50 mM.
Statistical analysis
Results were expressed as means 6 SE. Statistical analysis was performed
by using paired and unpaired Student’s t tests. p values , 0.05 were con-
sidered as statistically significant.
Results
PI3K inhibitors, wortmannin and LY294002, inhibit Ig binding
to FcaRr but not to FcgRII
IgA and IgG receptors on human eosinophils have been shown to
be modulated differentially by priming with Th2-derived cytokines
IL-4 and IL-5 (19). Stimulation of human eosinophils with optimal
concentrations of both IL-5 (1029) and IL-4 (1028) leads to a
time-dependent, transient activation of the lipid kinase PI3K, as
measured in antiphosphotyrosine immunoprecipitates (30). Prein-
cubation with 30 nM wortmannin, a relatively specific PI3K in-
hibitor, resulted in a complete inhibition of PI3K activation in
eosinophils stimulated with IL-5.
To investigate the involvement of PI3K in the cytokine-induced
Fc receptor activation on eosinophils, we performed rosette assays
in the presence of wortmannin or LY294002, which both inhibit
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PI3K activity through distinct mechanisms. Freshly isolated eo-
sinophils from normal donors only bind very weakly human serum
IgA-coated beads. Only 8% of the cells are able to form rosettes
(19). However, as shown previously, priming of eosinophils with
IL-4 or IL-5 dramatically changes the ability of these cells (50–
60%) to bind IgA-coated beads (Fig. 1A, open bars) (19). The
binding of IgG-coated beads to unprimed cells (25%) is also in-
creased by pre-incubation with IL-5, but IL-4 does not signifi-
cantly change the capacity of eosinophils to bind IgG-beads (19).
As shown in Fig. 1A, blocking of PI3K activation with wortmannin
(gray bars) or LY294002 (filled bars) completely inhibited the ro-
sette formation of IgA-coated beads with IL-4 or IL-5 primed eo-
sinophils. We have previously demonstrated that the concentra-
tions of wortmannin and LY294002 used here inhibit PI3K in
human eosinophils (30). This suggests a role for PI3K in the cy-
tokine-induced priming of IgA receptor functioning. In contrast,
the ability of IL-5 primed eosinophils to bind IgG beads is not
influenced by incubation with wortmannin or LY294002. (Fig.
1B). These results show that activation of the PI3K pathway is
involved in the specific priming of IgA-binding, but not crucial for
IL-5 induced priming of IgG-binding.
Phosphorylation and activation of MAPKs, ERK1 and ERK2, in
eosinophils after stimulation with Th2-derived cytokines IL-4
and IL-5
We have also studied the activation of ERK MAPKs to determine
their role in Fc receptor stimulation. First, we analyzed the ability
of IL-4 and IL-5 to induce activation of MAPKs ERK1 and ERK2,
which are both downstream targets of p21ras signal transduction.
To measure the kinase activity of both ERK1 and ERK2 after
stimulation, we specifically immunoprecipitated ERK1 or ERK2
and performed a kinase assay as described in Materials and Meth-
ods. As shown in Fig. 2, ERK1 kinase activity was minimally
effected by stimulation with IL-4 or IL-5, which is in agreement
with the unaltered levels of phosphorylation of ERK1 in eosino-
phils (30). Kinase activity of ERK2 was clearly induced by IL-5
(1029 M) stimulation but remained unaffected by IL-4 (5 3 1029
M) (Fig. 2). We have utilized a pharmacological inhibitor of the
p21ras-ERK pathway, PD98059, which has been described as a
specific inhibitor of MEK, the upstream kinase mediating activa-
tion of ERK1 and ERK2 by p21ras (31, 32). Pretreatment of eo-
sinophils with PD98059 (50 mM) resulted in an inhibition of
ERK2 activation after IL-5 stimulation as measured by MBP phos-
phorylation (Fig. 2, lower panel, lane 6).
Inhibition of MEK by PD98059 prevents binding of IgG but not
IgA to primed eosinophils
It is clear that ERK2 is activated in eosinophils after stimulation
with IL-5 and this activation can be inhibited by PD98059. We
thus studied the effect of the MEK inhibitor on Ig-rosette formation
with eosinophils to investigate whether the activation of ERKs is
involved in the modulation of Ig receptors.
Interestingly, whereas PI3K appeared to be critical for binding
of IgA beads (Fig. 1A), activation of ERKs is not required for
FcaR activation. Binding of IgA-coated beads to primed eosino-
phils was not inhibited by preincubation with 10 mM of the MEK
inhibitor, PD98059 (Fig. 3A, gray bars). Even a higher concentra-
tion, 50 mM, which completely inhibits ERK activation (Fig. 2)
does not significantly effect rosette formation with IgA beads (Fig.
3A, filled bars). However, 30-min incubation with PD98059 before
FIGURE 1. Effect of PI3K inhibitors, wortmannin and LY294002, on
the rosette formation of cytokine primed eosinophils with Ig-coated beads.
Freshly isolated eosinophils from normal donors were pretreated for 15
min at 37°C with buffer (open bars), 20 nM wortmannin (gray bars), or 1
mM LY294002 (filled bars) and subsequently stimulated at 37°C with IL-4
(1029 M) or IL-5 (1029 M) for 2 min or 15 min, respectively. After stim-
ulation, IL-4- and IL-5-primed cells were incubated for 20 and 30 min,
respectively, with magnetic dynabeads coated with human serum IgA (A)
or incubated with IgG beads (B) for IL-5-primed cells. Binding of Ig beads
to unprimed cells is presented by the control bars. Binding of beads is
expressed as rosette index (number of beads/100 cells). Mean values are
presented 6 SE (n 5 4). A paired Student’s t test was used to perform a
statistical analysis of each condition and the control. Statistical analysis of
each priming condition and the effect of inhibitors on this priming revealed
that values indicated with p differed significantly (p , 0.05).
FIGURE 2. Effect of cytokines on the activation of MAPKs, ERK1 and
ERK2, in eosinophils and the effect of MEK inhibitor PD98059. Eosino-
phils were incubated for 30 min at 37°C in the absence or presence of 50
mM PD98059 and subsequently stimulated with IL-4 (5 3 1029 M) or IL-5
(1029 M) for 5 or 15 min, respectively. After stimulation the cells were
lyzed and the MAPKs were specifically immunoprecipitated with either an
ERK1 (A) or ERK2 (B) Ab. Kinase activity was analyzed by the phos-
phorylation of the substrate MBP, which was detected by autoradiography.
The experiment shown is representative of at least three experiments.
FIGURE 3. Effect of MEK inhibitor PD98059 on the rosette formation of
cytokine primed eosinophils with Ig-coated beads. Eosinophils were pretreated
for 30 min at 37°C in the absence (open bars) or presence of 10 mM (gray bars)
or 50 mM (filled bars) PD98059 and subsequently stimulated at 37°C with IL-4
(1029 M) or IL-5 (1029 M) for 2 min or 15 min, respectively. After stimulation
primed cells were incubated with magnetic dynabeads coated with human
serum IgA (A) or incubated with IgG beads (B). The open bar at left represents
binding of Ig beads to unprimed cells as a control. Binding of beads is ex-
pressed as rosette index (number of beads/100 cells). Mean values are pre-
sented 6 SE (n 5 4). A paired Student’s t test was used to perform a statistical
analysis of each condition and the control. Values indicated with p differed
significantly (p , 0.05) from values obtained with cells that were not pre-
treated with inhibitors (open bars).
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IL-5 stimulation resulted in a 60% decrease of IgG binding. Levels
of IgG binding to PD98059 treated and IL-5-stimulated cells were
reduced to the levels of IgG binding to unprimed eosinophils
(Fig. 3B).
Th2-derived cytokines IL-4 and IL-5 stimulate phosphorylation
of p38 MAPK in eosinophils
Although p38 MAPK was initially described as being activated by
a variety of cellular stresses, it is now also known to be activated
in response to various inflammatory cytokines (33–35). We thus
studied the stimulation of p38 MAPK phosphorylation in human
eosinophils. Phosphorylation of p38 after stimulation with IL-4
and IL-5 was detected by Western blot analysis with an activation-
specific Ab that only interacts with Tyr182-phosphorylated p38. As
shown in Fig. 4A, upper panel, a phosphorylated form of p38 is
clearly detected in eosinophils that are stimulated for 15 min with
IL-5. However, stimulation with IL-4 induced a rapid but very
weak, transient phosphorylation of p38 MAPK. In all donors
tested, the phosphorylation of p38 had already diminished after
5-min stimulation with IL-4. This in contrast with p38 phosphor-
ylation by IL-5 that remained for at least 25 min (data not shown).
Reprobing of the blot with p38 antiserum (Fig. 4A, lower panel)
shows an equal amount of p38 protein in all lanes. Activation of
p38 MAPK is also shown in Fig. 4B. Although the level of p38
MAPK activity in unprimed cells was variable (compare first lanes
of both panels in Fig. 4B and first lane in Fig. 6), an increase of p38
MAPK activity was detected both in IL-4- and IL-5-stimulated
cells. Cytokine induced p38 MAPK activation could be blocked
completely by 1 mM of SB203580 (Fig. 4B, right lane of both
panels). This inhibitor, a pyridinyl imidazole compound, is a
highly selective inhibitor of p38 activity and has been used exten-
sively as a tool to evaluate p38 MAPK-dependent events in
vivo (36).
Inhibition of p38 by SB203580 prevents binding of IgA but not
IgG to primed eosinophils
To study a potential role for the activation of p38 kinase in acti-
vation of Fc receptors by Th2-derived cytokines, we studied the
binding capacity of primed eosinophils after addition of
SB203580. As shown in Fig. 5, inhibition of p38 in eosinophils
results in a striking difference in binding capacities of the cells to
either IgA or IgG beads. The effect of priming with both IL-4 and
IL-5 on IgA binding appears to be abolished by incubation with
SB203580. The effect of IL-4 priming on IgA rosette formation
(Fig. 5A) is dramatically decreased by pre-incubation with a 100
nM concentration of SB203580 (Fig. 5A, middle panel, gray bar),
and a higher concentration (1 mM) of the inhibitor totally blocks
the effect of IL-4 on rosette formation (Fig. 5A, middle panel, filled
bar). IL-5-primed binding of IgA beads is already completely in-
hibited by the lower concentration (100 nM) of SB203580 (Fig.
5A, right panel, gray bar). In contrast, IL-5-induced modulation of
FcgRII on eosinophils is not affected by pre-treatment with
SB203580 (Fig. 5B).
Inhibition of p38 by LY294002 and wortmannin
As suggested by Figs. 1 and 5, both activation of PI3K and p38
MAPK are involved in the modulation of FcaR on human eosin-
ophils. Since inhibition of either PI3K or p38 MAPK activity re-
sulted in a complete loss of IgA rosette formation, we questioned
whether PI3K and p38 MAPK may be components of a single
signal transduction pathway activated upon Th2-cytokine stimula-
tion. We investigated this possibility by performing p38 MAPK
assays with IL-5-primed eosinophils that were pretreated with the
PI3K inhibitors LY294002 and wortmannin. As shown in Fig. 6,
activation of p38 MAPK by IL-5 is blocked by inhibiting PI3K
activation by both LY294002 (1 mM) and wortmannin (30 nM),
FIGURE 4. Phosphorylation and activation of p38 MAPK in eosinophils after stimulation with Th2-derived cytokines IL-4 and IL-5. A, After stimulation
of the cells with either IL-4 or IL-5 (2 3 106 per condition) for indicated time, eosinophils were washed with ice-cold PBS, lyzed in lysis buffer, and heated
for 5 min after addition of 53 sample buffer. Phosphorylation of p38 was detected using a polyclonal antiphospho-p38 antiserum for Western blot analysis
(upper panel) and the blot was reprobed with a polyclonal anti-p38 Ab (lower panel). The experiment shown is representative of at least three experiments.
B, Kinase assays were performed with specifically immunoprecipitated p38 MAPK of IL-4 (5 3 1029 M; 5 min) or IL-5 (1029 M; 15 min) stimulated cells
in the presence or absence of 1 mM of SB203580. Kinase activity was analyzed by the phosphorylation of the substrate MBP, which was detected by
autoradiography. The experiment shown is representative of three experiments.
FIGURE 5. Effect of the p38 MAPK inhibitor SB203580 on the rosette
formation of cytokine primed eosinophils with Ig-coated beads. Cells were
pretreated for 15 min at 37°C in the absence (open bars) or presence of 100
nM (gray bars) or 1 mM (filled bars) SB203580 and subsequently stimu-
lated at 37°C with IL-4 (1029 M) or IL-5 (1029 M), for 2 min or 15 min,
respectively. Both IL-4- and IL-5-primed eosinophils were incubated with
IgA-coated beads for 20 and 30 min, respectively (A). For rosette assay
with IgG-coated beads only IL-5-stimulated cells were used and compared
with binding of Ig beads to unprimed eosinophils. Rosette index is the
measure of binding of the beads (number of beads/100 cells). Mean values
are presented 6 SE (n 5 3). Statistical analysis of each priming condition
and the effect of inhibitors on this priming revealed that values indicated
with p differed significantly (p , 0.05).
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suggesting that indeed PI3K and p38 MAPK are activated in the
same signal transduction pathway and that p38 MAPK is activated
downstream of PI3K.
Discussion
The phenotype of activated eosinophils in vivo is well described
and much is known concerning the importance of the eosinophil in
inflammatory diseases such as allergic asthma. It is also clear that
cytokines and chemoattractants are important modulators of eo-
sinophil functions in vivo, and several signal transduction path-
ways are activated in eosinophils after stimulation with these ago-
nists (30, 37). However, little is known about the molecular
mechanisms that finally lead to activation of eosinophils at specific
sites of inflammation. The hypothesis that there might be spatial
and temporal regulation of eosinophil priming by different cyto-
kines is an interesting concept to understand eosinophil activation
in patients with allergic diseases. As shown previously, receptors
for IgA and IgG on human eosinophils are differentially modulated
by Th2-derived cytokines IL-4 and IL-5 (19). In this study we
show that IL-4 and IL-5 activate Ig receptors by means of different
signal transduction pathways.
Binding of IL-5 to its receptor on eosinophils directly results in
association and activation of members of the JAK/STAT pathway
and phosphorylation and activation of several kinases (37, 38),
including the tyrosine kinase Lyn (37) as well as PI3K (30). The
IL-4R signals through a complex network of signaling molecules
(reviewed in Refs. 39 and 40) including members of JAK/STAT
pathway (41); PI3K (42); specific cellular substrates such as insu-
lin receptor substrate-2 (43, 44) and Cbl (45); and protein kinases
including Fes (46). In contrast with IL-5, IL-4 is unable to activate
the p21ras pathway, and ERK1 and ERK2 are not activated by IL-4
stimulation (47). Although tyrosine phosphorylation of multiple
proteins and PI3K activation by IL-4 stimulation are described in
several cells and cell lines, very little is known about IL-4 signal-
ing in human eosinophils.
As previously described IL-4 and IL-5 are potent activators of
PI3K (IL-4 and IL-5) and ERK2 (IL-5) (30), but this is the first
report demonstrating p38 MAPK activation in eosinophils. p38
MAPK (also known as CSBP, RK, and HOG1) is a recently iden-
tified protein kinase that shares sequence similarity with other
MAPKs. p38 MAPK is activated by the dual specific kinase
MKK3 following exposure to products of microbial pathogens,
environmental stress and pro-inflammatory cytokines (34, 48, 49).
It has previously been shown to be activated by cytokines such as
TNF-a, IL-1, and granulocyte-macrophage CSF in human
neutrophils (36, 50–52).
This is the first report to show that IL-4 and IL-5 are able to
activate p38 MAPK. Although p38 phosphorylation by IL-5 prim-
ing seems to be much stronger, both IL-4 and IL-5 are able to
induce p38 kinase activity, as shown in Fig. 4. This demonstrates
that downstream of the IL-4 and IL-5 receptors some signals con-
verge at the level of p38 MAPK. The specific nature of these
signals remains to be elucidated. To examine if there was a role of
p38 in IL-4- and IL-5-induced activation of Fc receptors, we uti-
lized the potent and highly selective inhibitor of p38 kinase,
SB203580 (36). This inhibitor has been useful in dissecting sig-
naling pathways involved in inflammatory responses. Our data
suggest that p38 activation also plays a role in the activation of Ig
receptors on human eosinophils. Cytokine-induced binding of IgA-
coated beads to human eosinophils was blocked by inhibition of
p38 activation (Fig. 5), since incubation of the cells with
SB203580 before IL-4 or IL-5 stimulation leads to a complete
inhibition in IgA binding. The kinetics of IL-4 priming on rosette
formation with IgA beads correlate with the fast induction of p38
MAPK phosphorylation by IL-4. This is different for IL-5-induced
p38 and ERK phosphorylation and IgA-binding, which is much
slower and remains activated for a longer duration.
The fact that inhibition of either the p38 MAPK or PI3K path-
way results in loss of IgA binding after priming demonstrates that
both pathways are involved in modulation of the IgA receptor on
eosinophils. It is tempting to speculate that p38 and PI3K might be
both components of one signal transduction pathway that is acti-
vated by both IL-4 and IL-5 and utilized for the priming of FcaR
activation. Since PI3K is a lipid kinase that is activated by trans-
location to the membrane, it is not likely that it will act down-
stream of p38. Activation of p38 by PI3K has previously been
suggested by Krump et al. (53), and here we show that p38 MAPK
activation can indeed be a downstream target of PI3K in eosino-
phils. Activation of p38 MAPK is dramatically decreased in eo-
sinophils in which PI3K activity is blocked by either LY294002 or
wortmannin (Fig. 6), suggesting that under these circumstances
PI3K activation is necessary for proper p38 activation.
We have also shown that In contrast with IgA binding, inhibi-
tion of PI3K and p38 MAPK activity do not influence the effect of
IL-5 on binding of IgG beads, suggesting that neither one of these
pathways plays a major role in FcgRII modulation by IL-5. Mod-
ulation of FcgRII functioning seem to require other signals includ-
ing the activation of the p21ras-ERK pathway, since inhibition of
this pathway with PD98059 results in a complete reduction of IgG
rosette formation after stimulation with IL-5. Therefore, it is not
surprising that IL-4 is not able to induce IgG binding to eosino-
phils (19), since IL-4 it cannot activate the p21ras pathway (54).
In Fig. 7, a model is presented for the hypothesis that selective
production of Th2-derived cytokines can lead to activation of dif-
ferent Ig receptors. This model predicts the distinction between
FcaR and FcgRII activation and the general signal transduction
pathways initiated by IL-5 compared with the more restricted ac-
tivities of IL-4. The control of receptor activation by priming
might be a critical process for the final activation of eosinophils.
The regulation of Fc receptor affinity on eosinophils is analogous
to the activation of integrins by diverse cellular stimuli. Both re-
ceptor types are controlled by inside-out signaling generated from
cytokine/chemotaxis receptors. Although inside-out signaling is
now well established for integrins (55), this is a novel concept for
Fc receptors.
Despite the clear phenotype of cytokine-activated eosinophils in
the context of Ig binding, not much is known about the mecha-
nisms responsible. Several possibilities can be suggested: 1) a con-
formational change of the receptor, leading to an affinity switch to
FIGURE 6. Effect of PI3K inhibitors LY294002 and wortmannin on
p38 MAPK activation. After preincubation at 37°C with either buffer,
LY294002 (1 mM; 15 min) or wortmannin (30 nM; 5 min), eosinophils
were subsequently stimulated with IL-5 (1029 M) for 15 min. A kinase
assay was performed with specifically immunoprecipitated p38 MAPK.
Detection of the phosphorylation of the substrate MBP by autoradiography
was a measurement for kinase activity. The experiment shown is repre-
sentative of three experiments.
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a higher affinity for Ig (56), and 2) membrane expression of re-
ceptors that are stored in secretory granules and released upon
triggering of the cells with cytokines. It has been described for
neutrophils that priming results in rapid mobilization of subcellular
granules to cell surface to increase the number of granule associ-
ated receptors (57). 3) During activation of leukocytes, co-capping
or clustering of integrin and Fc receptors can lead to an avidity
switch (58). 4) Cytokine-induced activation of Ig receptors on eo-
sinophils might be caused by inhibition of an inhibitory signal
which keeps the receptor in a nonfunctional state. A suppressive
regulation has been suggested to explain the default highly acti-
vated state of integrin avb3 when it is purified, in contrast with the
moderate affinity state of cellular avb3 (59). The hypothesis of an
“inside-out suppressor” is supported by the finding that adding
protein kinase C inhibitors to eosinophils leads to increased re-
sponsiveness of opsonized particles (60). Additional experiments
will be necessary to determine the precise nature of the signals
mediating these effects.
In conclusion, activation of Fc receptors appear to be a tightly
regulated process of inside-out signaling from cytokine receptors
leading to receptor activation. Production of specific cytokines by
Th2 lymphocytes leads to either a generalized priming phenotype
(IL-5/PI3K, p38 MAPK, and ERK2) associated with activation of
Ig receptors and integrin receptors or a restricted phenotype (IL-
4/PI3K and p38 MAPK) leading primarily to enhanced IgA recep-
tor functions. Elucidation of the mechanisms generated by the
aforementioned receptor-activated signals will lead to insight into
the mechanisms of eosinophil priming occurring in allergic dis-
eases in vivo.
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